CLIA Kit for Syndecan 1 (SDC1) Homo sapiens (Human) Sandwich CLIA

CD138; SDC; SYND1; Syndecan Proteoglycan 1

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Syndecan 1 (SDC1) Packages (Simulation)
  • CLIA Kit for Syndecan 1 (SDC1) Packages (Simulation)
  • CLIA Kit for Syndecan 1 (SDC1) Results demonstration
  • SCB966Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Syndecan 1 (SDC1) and the recovery rates were calculated by comparing the measured value to the expected amount of Syndecan 1 (SDC1) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 98-105 102
EDTA plasma(n=5) 98-105 101
heparin plasma(n=5) 81-102 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Syndecan 1 (SDC1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Syndecan 1 (SDC1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Syndecan 1 (SDC1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 95-102% 97-105% 81-93% 80-99%
EDTA plasma(n=5) 91-101% 87-96% 84-105% 89-98%
heparin plasma(n=5) 98-105% 89-105% 82-102% 79-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Syndecan 1 (SDC1)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Syndecan 1 (SDC1). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Syndecan 1 (SDC1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Syndecan 1 (SDC1) level in the sample or standard.;

Citations

  • Increased level of soluble syndecan-1 in serum correlates with myocardial expression in a rat model of myocardial infarctionSpringerLink: a201w3l18k257462
  • Sdc1 Overexpression Inhibits the p38 MAPK Pathway and Lessens Fibrotic Ventricular Remodeling in MI RatsSpringer: Source
  • Damage of the endothelial glycocalyx in chronic kidney diseasePubmed:24727235
  • Effect of valproic acid and injury on lesion size and endothelial glycocalyx shedding in a rodent model of isolated traumatic brain injuryPubmed:25058256
  • Impairment of the Endothelial Glycocalyx in Cardiogenic Shock and its Prognostic RelevancePubmed:25692257
  • Dexamethasone Suppressed LPS-Induced Matrix Metalloproteinase and Its Effect on Endothelial Glycocalyx SheddingPubMed: 26199464
  • Platelet-Derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury.PubMed: 26371596
  • Dual antiplatelet and anticoagulant APAC prevents experimental ischemia–reperfusion-induced acute kidney injurypubmed:27405618
  • Endothelial glycocalyx layer shedding following lung resectionpubmed:27643669
  • Resuscitation with Pooled and Pathogen-Reduced Plasma Attenuates the Increase in Brain Water Content following Traumatic Brain Injury and Hemorrhagic Shock in Rats10.1089
  • Resuscitation with pooled and pathogen-reduced plasma attenuates the increase in brain water content following traumatic brain injury and hemorrhagic shock in rats the rat.doi/10.1089/neu.2016.4574
  • Volume kinetics of Ringer's lactate solution in acute inflammatory disease10.1016:j.bja.2018.04.023
  • MPO (myeloperoxidase) reduces endothelial glycocalyx thickness dependent on its cationic chargePubmed:29903730
  • Plasma resuscitation improved survival in a cecal ligation and puncture rat model of sepsisPubmed:28591008
  • Experimental models of endotheliopathy: impact of shock severityPubmed:28697004
  • Effects of propranolol and clonidine on brain edema, blood-brain barrier permeability, and endothelial glycocalyx disruption after fluid percussion brain injury in the ratPubmed:28930945
  • The Endothelial Glycocalyx in the Peritoneal Microcirculation of Rats with Chronic Kidney Failure Exposed to Dialysis Solutions173015_06.pdf
  • Plasma ameliorates endothelial dysfunction in burn injuryDoi: 10.1016/j.jss.2018.08.027
  • Dexmedetomidine preserves the endothelial glycocalyx and improves survival in a rat heatstroke modelPubmed: 30374889
  • Postoperative microcirculatory perfusion and endothelial glycocalyx shedding following cardiac surgery with cardiopulmonary bypassPubmed: 30687934
  • Microvascular alterations during cardiac surgery using a heparin or phosphorylcholine coated circuitPubmed: 31787433
  • Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis: Syndecan-1, glypican-3 and ICPPubmed: 31919038
  • Heparin Binding Protein and Endothelial Glycocalyx Markers in Severe COVID-19–A Prospective Observational Cohort Study
  • Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis33375342
  • Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency34119534
  • The effect of pre-operative methylprednisolone on postoperative delirium in elderly patients undergoing gastrointestinal surgery: a randomized, double-blind, placebo …34423832
  • Inhalation of 2% hydrogen improves survival rate and attenuates shedding of vascular endothelial glycocalyx in rats with heat stroke34524269
  • Dexmedetomidine suppresses serum syndecan-1 elevation and improves survival in a rat hemorrhagic shock modelPubmed:35110424
  • Resuscitation of hemorrhagic shock using normal saline does not damage the glycocalyx in the immediate resuscitation phase

Recommend products